Filgrastim

Generic Name
Filgrastim
Brand Names
Accofil, Granix, Grastofil, Neupogen, Nivestim, Nivestym, Ratiograstim, Releuko, Zarxio, Zarzio, Filgrastim Hexal, Tevagrastim
Drug Type
Biotech
Chemical Formula
-
CAS Number
121181-53-1
Unique Ingredient Identifier
PVI5M0M1GW
Background

Filgrastim is a short-acting recombinant, non-pegylated human granulocyte colony-stimulating factor (G-CSF) analog produced by recombinant DNA technology. It has an amino acid sequence identical to endogenous G-CSF, but it is non-glycosylated unlike the endogenous G-CSF and has an N-terminal methionine added in the sequence for expression in E. Coli. Human G...

Indication

Filgrastim is indicated to decrease the incidence of infection‚ as manifested by febrile neutropenia‚ in patients with nonmyeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a significant incidence of severe neutropenia with fever.
...

Associated Conditions
Congenital neutropenia, Cyclic neutropenia, Febrile Neutropenia, Hematopoietic Subsyndrome of Acute Radiation Syndrome, Idiopathic neutropenia, Infection, Neutropenia
Associated Therapies
Mobilization of hematopoietic progenitor cells into peripheral blood for collection by leukapheresis therapy
Clinical Trials
Related News

Part II: Granulocyte-Colony Stimulating Factor Adjunct Therapy for Biliary Atresia

Phase 2
Recruiting
Conditions
Biliary Atresia
Interventions
Drug: Filgrastim
First Posted Date
2020-05-05
Last Posted Date
2023-09-08
Lead Sponsor
Holterman, Ai-Xuan, M.D.
Target Recruit Count
400
Registration Number
NCT04373941
Locations
🇻🇳

Nation Children's Hospital, Hanoi, Dong Da District, Vietnam

🇻🇳

Children Hospital 1, Ho Chi Minh City, Vietnam

🇵🇰

Aga Khan University, Karachi, Pakistan

and more 1 locations

Matched Related and Unrelated Donor Stem Cell Transplantation for Severe Combined Immune Deficiency (SCID): Busulfan-based Conditioning With h-ATG, Radiation, and Sirolimus

First Posted Date
2020-05-01
Last Posted Date
2024-12-20
Lead Sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
Target Recruit Count
30
Registration Number
NCT04370795
Locations
🇺🇸

National Institutes of Health Clinical Center, Bethesda, Maryland, United States

Cytokine-induced Memory-like NK Cells in Combination With Chemotherapy in Pediatric Patents With Refractory or Relapsed AML

First Posted Date
2020-04-21
Last Posted Date
2023-04-04
Lead Sponsor
Washington University School of Medicine
Registration Number
NCT04354025

Efficacy and Safety of Cladribine in Combination With CAG in Newly Diagnosed Unfit Patients With AML

First Posted Date
2020-02-05
Last Posted Date
2020-12-17
Lead Sponsor
Sun Yat-sen University
Target Recruit Count
34
Registration Number
NCT04254640
Locations
🇨🇳

Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China

Stem Cell Transplantation in Crohn's Disease

First Posted Date
2020-01-13
Last Posted Date
2024-04-10
Lead Sponsor
Cedars-Sinai Medical Center
Target Recruit Count
15
Registration Number
NCT04224558
Locations
🇺🇸

Cedars-Sinai Medical Center, Los Angeles, California, United States

Autologous Transplant Targeted Against Crohn's

First Posted Date
2019-11-06
Last Posted Date
2019-11-08
Lead Sponsor
Northwestern University
Registration Number
NCT04154735
Locations
🇺🇸

Northwestern University, Chicago, Illinois, United States

PRIMUS 001: A Study Looking at Two Different Chemotherapy Regimens in Patients With Metastatic Pancreatic Cancer

First Posted Date
2019-11-05
Last Posted Date
2024-02-08
Lead Sponsor
Judith Dixon-Hughes
Target Recruit Count
500
Registration Number
NCT04151277
Locations
🇬🇧

Royal Marsden Hospital, London, United Kingdom

🇬🇧

Poole Hospital, Poole, United Kingdom

🇬🇧

Freeman Hospital, Newcastle, United Kingdom

and more 27 locations

Evaluation of LY2606368 Therapy in Combination With Cyclophosphamide or Gemcitabine for Children and Adolescents With Refractory or Recurrent Group 3/Group 4 or SHH Medulloblastoma Brain Tumors

First Posted Date
2019-07-17
Last Posted Date
2024-03-26
Lead Sponsor
St. Jude Children's Research Hospital
Target Recruit Count
21
Registration Number
NCT04023669
Locations
🇺🇸

St. Jude Children's Research Hospital, Memphis, Tennessee, United States

Bendamustine With or Without Cyclophosphamide in Preventing GVHD in Patients Undergoing Stem Cell Transplant

First Posted Date
2019-07-17
Last Posted Date
2024-12-12
Lead Sponsor
M.D. Anderson Cancer Center
Target Recruit Count
25
Registration Number
NCT04022239
Locations
🇺🇸

M D Anderson Cancer Center, Houston, Texas, United States

Granulocyte Colony Stimulating Factor Versus Platelet Rich Plasma and Outcomes of Frozen Embryo Transfer

First Posted Date
2019-05-10
Last Posted Date
2023-10-16
Lead Sponsor
Wael Elbanna Clinic
Target Recruit Count
390
Registration Number
NCT03945812
Locations
🇪🇬

Hayat center, Maadi, Cairo, Egypt

© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy